New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTDELL, LULU, WSO, FISV, UAL, AMTD, AXP, BHP, SYA, VRTX, SIRO, REGN, PAAS, BIIB, SSRI, PFG, LOGI, AFL, RKT, PDCO, DY, ARMHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Equal Weight from Overweight at Morgan Stanley... Aflac (AFL) downgraded to Neutral from Buy at Sterne Agee... Biogen (BIIB) downgraded to Neutral from Buy at BofA/Merrill... Dycom (DY) downgraded to Outperform from Strong Buy at Raymond James... Logitech (LOGI) downgraded to Underperform from Neutral at Credit Suisse... Pan American Silver (PAAS) downgraded to Hold from Buy at Deutsche Bank... Patterson Companies (PDCO) downgraded to Sell from Neutral at Goldman... Principal Financial (PFG) downgraded to Neutral from Buy at Sterne Agee... Regeneron (REGN) downgraded to Hold from Buy at Jefferies... Rock-Tenn (RKT) downgraded to Buy from Conviction Buy at Goldman... Silver Standard (SSRI) downgraded to Sell from Hold at Deutsche Bank... Sirona Dental (SIRO) downgraded to Neutral from Buy at Goldman... Symetra Financial (SYA) downgraded to Underperform from Neutral at Sterne Agee... TD Ameritrade (AMTD) downgraded to Neutral from Buy at Sterne Agee... Watsco (WSO) downgraded to Neutral from Outperform at RW Baird... BHP Billiton (BHP) downgraded to Hold from Buy at Dahlman Rose... United Continental (UAL) downgraded to Neutral from Overweight at JPMorgan... Vertex (VRTX) downgraded to Neutral from Buy at Lazard Capital... American Express (AXP) downgraded to Underweight from Neutral at JPMorgan... Fiserv (FISV) downgraded to Equal Weight from Overweight at First Analysis... lululemon (LULU) downgraded to Underperform from Neutral at Buckingham... Dell (DELL)downgraded to Neutral from Buy at Monness Crespi.
News For ARMH;AFL;BIIB;DY;LOGI;PAAS;PDCO;PFG;REGN;RKT;SSRI;SIRO;SYA;AMTD;WSO;BHP;UAL;VRTX;AXP;FISV;LULU;DELL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 19, 2015
18:01 EDTAFLAflac names Matthew Owenby as Chief Human Resources Officer
Subscribe for More Information
16:12 EDTDYDycom reports Q3 total revenue $456.93M, consensus $468.2M
16:11 EDTDYDycom sees Q4 EPS 74c-82c, consensus 58c
Subscribe for More Information
16:10 EDTDYDycom reports Q3 EPS 58c, consensus 37c
Subscribe for More Information
15:00 EDTDYNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Analog Devices (ADI), consensus 72c... Autodesk (ADSK), consensus 28c... Computer Sciences Corporation (CSC), consensus $1.20... Qihoo 360 Technology (QIHU), consensus 49c... Keysight Technologies (KEYS), consensus 65c... Nordson (NDSN), consensus 86c... ViaSat (VSAT), consensus 42c... Dycom Industries (DY), consensus 37c.
09:58 EDTBHPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:01 EDTSIROSirona Dental, OnDemand 3D enter into settlement, license agreement
Sirona and OnDemand 3D Technology announced that the companies have entered into a settlement and license agreement to resolve the pending litigation concerning Sirona’s U.S. Patent No. 6,319,006, which covers methods of planning dental surgical drill guides. OnDemand 3D has agreed to an up-front payment and ongoing royalties to Sirona. Under the agreement, OnDemand acknowledges both the validity of Sirona’s patent and also the infringement of the OnDemand In2Guide product. Sirona has granted OnDemand a limited license to use a modified version of its In2Guide to plan a dental surgical drill guide that must be fabricated at a central facility, but is restricted from using the software to plan the fabrication of a chairside surgical drill guide.
08:23 EDTUALSenate Commerce, Science & Transportation Committee to hold a hearing
Subscribe for More Information
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:32 EDTAXPPacific Crest shifts preference to MasterCard, upgrades to buy
Pacific Crest analyst Josh Beck shifted his preference to MasterCard (MA) from Visa (V) and upgraded the stock to Overweight from Sector Weight. Beck believes interchange legislation in Europe may have an unintended consequence of benefiting global open-loop payment networks, favoring both MasterCard and Visa. The changes are also positive for eBay's (EBAY) PayPal and mixed for American Express (AXP), Beck tells investors today in a research note. He points out his preference for MasterCard relative to Visa follows the latter company's outperformance over the past year. Beck has a $110 price target for MasterCard shares. The stock closed yesterday down 14c to $93.08.
07:16 EDTBHPBHP Billiton downgraded to Reduce from Hold at HSBC
Subscribe for More Information
07:13 EDTAMTDBarclays to hold a conference
Subscribe for More Information
07:11 EDTUALWolfe Research to hold a conference
Subscribe for More Information
May 18, 2015
12:34 EDTREGNRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
12:09 EDTAXPAmerican Express management to meet with Guggenheim
Meeting to be held in New York on May 20 hosted by Guggenheim.
08:03 EDTRKTMeadWestvaco, RockTenn combined company name to be WestRock
Subscribe for More Information
07:46 EDTAXPAmerican Express has $850M revenue opportunity with Plenti, says Deutsche Bank
Deutsche Bank estimates the coalition loyalty/rewards program Plenti represents a $750M-$850M annual revenue opportunity for American Express (AXP) over the next 3-5 years. Earnings accretion will take time, but returns on equity are likely "very high," Deutsche says in a research note. The firm believes Plenti is an example of how Amex is leveraging its strengths to mitigate the loss of Costco (COST). It thinks Plenti's next program supplier needs to be a grocery chain, and pegs Whole Foods (WFM) as a good candidate. Deutsche keeps a Buy rating on American Express with a $90 price target.
06:09 EDTUALTrade group sees airlines carrying record passenger loads this summer, WSJ says
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
13:37 EDTAMTDTD Ameritrade shares look vulnerable in the near-term, Barron's says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use